Inhibitors of factor VIII in black patients with hemophilia

New England Journal of Medicine

Volumn 360, Issue 16, 2009, Pages 1618-1627

  Viel, Kevin R ^a   Ameri, Afshin ^b   Abshire, Thomas C ^c   Iyer, Rathi V ^d   Watts, Raymond G ^e   Lutcher, Charles ^b   Channell, Cynthia ^c   Cole, Shelley A ^a   Fernstrom, Karl M ^c   Nakaya, Shelley ^f   Kasper, Carol K ^g,h   Thompson, Arthur R ^f   Almasy, Laura ^a   Howard, Tom E ^g,i,j  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h JOINT REPLACEMENT INSTITUTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; ALLOANTIBODY; ANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; F8 PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; BLOOD CLOTTING FACTOR 8 GENE; BLOOD TRANSFUSION; CONTROLLED STUDY; DISEASE SEVERITY; FAMILY; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; HAPLOTYPE; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MISSENSE MUTATION; MUTATIONAL ANALYSIS; MUTATOR GENE; NEGRO; NONSENSE MUTATION; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICING DEFECT; ADULT; AMINO ACID SEQUENCE; CHILD; ETHNOLOGY; GENETICS; IMMUNOLOGY; MALE; MUTATION; PRESCHOOL CHILD; RISK FACTOR;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AMINO ACID SEQUENCE; ANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; FACTOR VIII; HAPLOTYPES; HEMOPHILIA A; HUMANS; ISOANTIBODIES; MALE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; YOUNG ADULT;

EID: 64749096663     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa075760     Document Type: Article

References (53)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9:418-435 (Pubitemid 36874391)
2. Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost 2004;2:1082-1095
3. Goodeve A. The incidence of inhibitor development according to specific mutations - and treatment? Blood Coagul Fibrinolysis 2003;14:Suppl 1:S17-S21.
4. Oldenburg J, Grimm T, Becker J, Olek K, Brackmann HH, Schwaab R. Mutations in severe hemophilia A: distribution within the factor VIII gene, origin and influence on inhibitor development. Beitr Infusionsther Transfusionsmed 1997;34:224-230
5. Oldenburg J, Schröder J, Brackmann HH, Müller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004;41:82-88 (Pubitemid 38182722)
6. Schröder J, El-Maarri O, Schwaab R, Müller CR, Oldenburg J. Factor VIII intron-1 inversion: frequency and inhibitor prevalence. J Thromb Haemost 2006;4:1141-1143
7. Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995;74:1402-1406
8. Lorenzo JI, López A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001;113:600-603 (Pubitemid 32524377)
9. Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006;107:46-51.
10. Addiego JE Jr, Kasper C, Abildgaard C, et al. Increased frequency of inhibitors in African American hemophilia A patients. Blood 1994;84:Suppl:239a. abstract.
11. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998;4:68.
12. Astermark J, Berntorp E, White GC, Kroner BL. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001;7:267-272 (Pubitemid 32471960)
13. Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994;83:2428-2435
14. Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 1984;150:19-29.
15. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and development of inhibitors. N Engl J Med 1993;328:453-459 (Pubitemid 23056434)
16. Rothschild C, Laurian Y, Satre EP, et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998;80:779-783
17. Viel KR, Machiah DK, Warren DM, et al. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 2007;109:3713-3724
18. Howard TE, Machiah DK, Tran TT, et al. African-Americans express multiple haplotypic forms of the wildtype factor VIII (FVIII) protein: a possible role for pharmacogenetics in FVIII inhibitor development? Blood 2004;104:113a. abstract.
19. Thompson AR. Structure and function of the factor VIII gene and protein. Semin Thromb Hemost 2003;29:11-22. (Pubitemid 36250259)
20. Mansvelt EP, Laffan M, McVey JH, Tuddenham EG. Analysis of the F8 gene in individuals with high plasma factor VIII: C levels and associated venous thrombosis. Thromb Haemost 1998;80:561-565
21. Gitschier J. Remembrances of factor VIII. 1. The race to the gene. J Thromb Haemost 2004;2:383-387
22. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984;312:326-330
23. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984;312:342-347
24. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984;312:337-342
25. Benjamin RJ, Busch MP, Fang CT, et al. Human immunodeficiency virus-1 infection correlates strongly with herpes simplex virus-2 (genital herpes) seropositivity in South African and United States blood donations. Transfusion 2008;48:295-303.
26. Garratty G, Glynn SA, McEntire R. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion 2004;44:703-706
27. Glynn SA, Schreiber GB, Murphy EL, et al. Factors influencing the decision to donate: racial and ethnic comparisons. Transfusion 2006;46:980-990
28. Wang B, Higgins MJ, Kleinman S, et al. Comparison of demographic and donation profiles and transfusion-transmissible disease markers and risk rates in previously transfused and nontransfused blood donors. Transfusion 2004;44:1243-1251
29. Kemball-Cook G, Tuddenham EG, Wacey AI. The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucleic Acids Res 1998;26:216-219
30. Howard TE, Machiah DK, Viel KR, et al. The Pharmacogenetics and Inhibitor Risk (PIR) Study: establishing the spectrum of factor (F)VIII gene (F8) mutations in African-American hemophilia A patients. Blood 2005;106:896a. abstract.
31. Kasper CK, Aledort L, Aronson D, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975;34:612.
32. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995;73:247-251
33. White GC II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85:560. (Pubitemid 32233035)
34. Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 1998;8:175-185
35. Ewing B, Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 1998;8:186-194
36. Bagnall RD, Giannelli F, Green PM. Int22h-related inversions causing hemophilia A: a novel insight into their origin and a new more discriminant PCR test for their detection. J Thromb Haemost 2006;4:591-598
37. Bagnall RD, Waseem N, Green PM, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood 2002;99:168-174 (Pubitemid 34532979)
38. Rossetti LC, Radic CP, Larripa IB, De Brasi CD. Genotyping the hemophilia inversion hotspot by use of inverse PCR. Clin Chem 2005;51:1154-1158 (Pubitemid 43079392)
39. Astermark J, Oldenburg J, Carlson J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006;108:3739-3745
40. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006;107:3167-3172
41. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006;12:Suppl 6:15-22.
42. Jayandharan G, Shaji RV, Baidya S, Nair SC, Chandy M, Srivastava A. Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions. Haemophilia 2005;11:481-491 (Pubitemid 41283117)
43. Repessé Y, Slaoui M, Ferrandiz D, et al. Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development. J Thromb Haemost 2007;5:1469-1476
44. Santacroce R, Acquila M, Belvini D, et al. Identification of 217 unreported mutations in the F8 gene in a group of 1,410 unselected Italian patients with hemophilia A. J Hum Genet 2008;53:275-284
45. Ma GC, Chang SP, Chen M, Kuo SJ, Chang CS, Shen MC. The spectrum of the factor 8 (F8) defects in Taiwanese patients with haemophilia A. Haemophilia 2008;14:787-795
46. Castaman G, Giacomelli SH, Ghiotto R, et al. Spectrum of mutations in Albanian patients with haemophilia A: identification of ten novel mutations in the factor VIII gene. Haemophilia 2007;13:311-316
47. David D, Ventura C, Moreira I, et al. The spectrum of mutations and molecular pathogenesis of hemophilia A in 181 Portuguese patients. Haematologica 2006;91:840-843
48. Howard TE, Viel KR, Fernstrom KM, et al. Allelically mismatched replacement therapy due to common African-restricted haplotypes of the factor (F)VIII protein may underlie the increased incidence of FVIII inhibitors observed in hemophilia-A patients of African-descent. Blood 2006;108:230a. abstract.
49. Kittles RA, Chen W, Panguluri RK, et al. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 2002;110:553-560
50. Redden DT, Allison DB. The effect of assortative mating upon genetic association studies: spurious associations and population substructure in the absence of admixture. Behav Genet 2006;36:678-686 (Pubitemid 44188083)
51. Tsai HJ, Kho JY, Shaikh N, et al. Ad-mixture-matched case-control study: a practical approach for genetic association studies in admixed populations. Hum Genet 2006;118:626-639
52. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006;4:2576-2581
53. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007;5:263-265 (Pubitemid 46139449)